MEET LEANN

51-year-old female

Data analyst; spends workday using a computer

Medical History

- Had **LASIK 10 years prior; diagnosed with DED** one year later
- First tried **OTC artificial tears** but only had temporary relief; then tried **warm compresses** and **lid scrubs** with no reported benefits
- **Tried Rx drops:** cyclosporine 7 years ago (discontinued after 6 months) and lifitegrast 2 years ago (discontinued after 3 months); **reported burning** on instillation with both

Chief Complaints

- **Moderate-to-severe eye dryness** and **difficulty concentrating** on a computer screen worsen throughout the day and affect her work performance
- Vision becomes **intermittently "very blurry"** when looking at a screen but **temporarily clears with blinking or artificial tear instillation**

Initial Observations

- **Red, watery** eyes
- Sensitivity to **light**

DED, dry eye disease.

INDICATION

MIEBO™ (perfluorohexyloctane ophthalmic solution) is a semifluorinated alkane indicated for the treatment of the signs and symptoms of dry eye disease.

IMPORTANT SAFETY INFORMATION

- MIEBO should not be administered while wearing contact lenses. Contact lenses should be removed before use and for at least 30 minutes after administration of MIEBO

Please see additional Important Safety Information on next page.

Click here for full Prescribing Information for MIEBO.

Miebo™
(perfluorohexyloctane ophthalmic solution)

MEET LEANN

NEXT STEPS

Based on Leann's history and presentation, **what assessments would you perform?**

What results would you expect to find?

What would be **your proposed treatment plan** to address Leann's dry eye disease?

Discover how MIEBO could provide patients like Leann with **relief from the signs and symptoms** of dry eye disease.

Learn more at MIEBO-ECP.COM.

IMPORTANT SAFETY INFORMATION (CONTINUED)

- Instruct patients to instill one drop of MIEBO into each eye four times daily
- The safety and efficacy in pediatric patients below the age of 18 have not been established
- The most common ocular adverse reaction was blurred vision (1% to 3% of patients reported blurred vision and conjunctival redness)

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

Please see additional Important Safety Information on previous page.

Click here for full Prescribing Information for MIEBO.

BAUSCH + LOMB

MBO.0408.USA.23

Miebo™
(perfluorohexyloctane ophthalmic solution)